These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24336756)

  • 1. Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody.
    Czaja CA; Merkel PA; Chan ED; Lenz LL; Wolf ML; Alam R; Frankel SK; Fischer A; Gogate S; Perez-Velez CM; Knight V
    Clin Infect Dis; 2014 Mar; 58(6):e115-8. PubMed ID: 24336756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.
    Browne SK; Zaman R; Sampaio EP; Jutivorakool K; Rosen LB; Ding L; Pancholi MJ; Yang LM; Priel DL; Uzel G; Freeman AF; Hayes CE; Baxter R; Cohen SH; Holland SM
    Blood; 2012 Apr; 119(17):3933-9. PubMed ID: 22403254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated Nontuberculous Mycobacterial Infection in a Patient with Anti-IFN-γ Autoantibodies.
    Tanimizu M; Mizuno K; Hashimoto M
    Acta Med Okayama; 2017 Dec; 71(6):547-552. PubMed ID: 29276230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent Mycobacterium abscessus infection secondary to interferon-γ autoantibodies.
    Naik R; Cortes JA
    Ann Allergy Asthma Immunol; 2016 May; 116(5):461-2. PubMed ID: 27009440
    [No Abstract]   [Full Text] [Related]  

  • 5. Disseminated Mycobacterium gordonae and Mycobacterium mantenii infection with elevated anti-IFN-γ neutralizing autoantibodies.
    Hase I; Morimoto K; Sakagami T; Kazumi Y; Ishii Y; van Ingen J
    J Infect Chemother; 2015 Jun; 21(6):468-72. PubMed ID: 25735882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection.
    Valour F; Perpoint T; Sénéchal A; Kong XF; Bustamante J; Ferry T; Chidiac C; Ader F;
    Emerg Infect Dis; 2016 Jun; 22(6):1124-1126. PubMed ID: 27192204
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab Restores IFN-γ-STAT1 Function and Ameliorates Disseminated Mycobacterium avium Infection in a Patient with Anti-Interferon-γ Autoantibody.
    Koizumi Y; Sakagami T; Nishiyama N; Hirai J; Hayashi Y; Asai N; Yamagishi Y; Kato H; Hagihara M; Sakanashi D; Suematsu H; Ogawa K; Mikamo H
    J Clin Immunol; 2017 Oct; 37(7):644-649. PubMed ID: 28779413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing QuantiFERON for Detection of Neutralizing Interferon-γ Autoantibodies in Patients With Nontuberculous Mycobacterial Infections.
    Suárez I; Lehmann C; Gruell H; Graeb J; Kochanek M; Fätkenheuer G; Plum G; van Wengen A; van de Vosse E; Hartmann P; Hanitsch LG; Rybniker J
    Clin Infect Dis; 2017 Aug; 65(3):518-521. PubMed ID: 28430999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple infection with Cryptococcus, varicella-zoster virus, and Mycobacterium abscessus in a patient with anti-interferon-gamma autoantibodies: a case report.
    Rujirachun P; Sangwongwanich J; Chayakulkeeree M
    BMC Infect Dis; 2020 Mar; 20(1):232. PubMed ID: 32188404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenicity of Mycolicibacterium phlei, a non-pathogenic nontuberculous mycobacterium in an immunocompetent host carrying anti-interferon gamma autoantibodies: a case report.
    Tanaka S; Hoshino Y; Sakagami T; Fukano H; Matsui Y; Hiranuma O
    BMC Infect Dis; 2019 May; 19(1):454. PubMed ID: 31117976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disseminated
    Chaononghin S; Visuttichaikit S; Apisarnthanarak A; Khawcharoenporn T
    Int J Mycobacteriol; 2020; 9(1):91-94. PubMed ID: 32474495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with acquired Anti IFN- γ autoantibody in patients with nontuberculous mycobacterial infection.
    Phoompoung P; Ankasekwinai N; Pithukpakorn M; Foongladda S; Umrod P; Suktitipat B; Mahasirimongkol S; Kiertiburanakul S; Suputtamongkol Y
    PLoS One; 2017; 12(4):e0176342. PubMed ID: 28437431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of Interferon-γ Neutralizing Autoantibodies Against Disseminated Nontuberculous Mycobacterial Disease.
    Aoki A; Sakagami T; Yoshizawa K; Shima K; Toyama M; Tanabe Y; Moro H; Aoki N; Watanabe S; Koya T; Hasegawa T; Morimoto K; Kurashima A; Hoshino Y; Trapnell BC; Kikuchi T
    Clin Infect Dis; 2018 Apr; 66(8):1239-1245. PubMed ID: 29126235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAPHO syndrome-like presentation of disseminated nontuberculous mycobacterial infection in a case with neutralizing anti-IFNγ autoantibody.
    Furuya H; Ikeda K; Miyachi K; Nakamura K; Suzuki K; Furuta S; Tamachi T; Hirose K; Sakagami T; Nakajima H
    Rheumatology (Oxford); 2017 Jul; 56(7):1241-1243. PubMed ID: 28371927
    [No Abstract]   [Full Text] [Related]  

  • 15. Disseminated Mycobacterium abscessus subsp. massiliense infection in a Good's syndrome patient negative for human immunodeficiency virus and anti-interferon-γ autoantibody: a case report.
    Imoto W; Yamada K; Hajika Y; Okamoto K; Myodo Y; Niki M; Kuwabara G; Yamairi K; Shibata W; Yoshii N; Nakaie K; Yoshizawa K; Namikawa H; Watanabe T; Asai K; Moro H; Kaneko Y; Kawaguchi T; Itoh Y; Kakeya H
    BMC Infect Dis; 2020 Jun; 20(1):431. PubMed ID: 32563248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review.
    Hase I; Morimoto K; Sakagami T; Ishii Y; van Ingen J
    Diagn Microbiol Infect Dis; 2017 Aug; 88(4):308-315. PubMed ID: 28633901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies.
    Ochoa S; Ding L; Kreuzburg S; Treat J; Holland SM; Zerbe CS
    Clin Infect Dis; 2021 Jun; 72(12):2206-2208. PubMed ID: 32745179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections.
    Chi CY; Lin CH; Ho MW; Ding JY; Huang WC; Shih HP; Yeh CF; Fung CP; Sun HY; Huang CT; Wu TS; Chang CY; Liu YM; Feng JY; Wu WK; Wang LS; Tsai CH; Ho CM; Lin HS; Chen HJ; Lin PC; Liao WC; Chen WT; Lo CC; Wang SY; Kuo CY; Lee CH; Ku CL
    Medicine (Baltimore); 2016 Jun; 95(25):e3927. PubMed ID: 27336882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-γ autoantibodies in patients with disseminated nontuberculous mycobacterial infection.
    Wu UI; Chuang YC; Sheng WH; Sun HY; Jhong YT; Wang JY; Chang SC; Wang JT; Chen YC
    Clin Microbiol Infect; 2018 Feb; 24(2):159-165. PubMed ID: 28694201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recurrent atypical mycobacterial infections in the adult: think of autoantibodies against interferon-gamma !].
    Picque JB; Blot M; Binois R; Jeudy G; Simonet AL; Cagnon J; Mahy S; Duong M; Buisson M; Chavanet P; Piroth L
    Rev Med Interne; 2012 Feb; 33(2):103-6. PubMed ID: 22236500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.